BactiVac Network Advisory Board (NAB)

Terms of Reference

Overall remit
The BactiVac Network Advisory Board (NAB) is composed of senior members of the bacterial vaccinology community and is responsible for providing non-binding but informed guidance to the BactiVac Management Oversight Board.

Terms of Reference
1. To provide informed advice and guidance on the network’s strategy
2. To witness the development of the BactiVac Network and gauge whether it is meeting its key objectives
3. To provide guidance to the BactiVac Management Oversight Board in selecting appropriate new directions
4. To make suggestions to improve the network’s performance in key areas, including network membership and the focus for the distribution of catalyst and other network funding
5. To provide guidance and arbitration where there is disagreement among the Management Oversight Board.

Duties of members of the Advisory Board:
- To act in the best interests of the BactiVac Network
- To act in good faith and with integrity
- To exercise due care and diligence
- To disclose and avoid any conflicts of interest
- To respect the confidentiality of those matters so classified
- Not to use their position to gain advantage for themselves or others
- Members are also expected to observe the 7 principles of public life identified by the Committee on Standards in Public Life (the Nolan Committee): selflessness, integrity, objectivity, accountability, openness, honesty, leadership.
Membership:

The constitution of the Advisory Board will be reviewed on an annual basis and revised, if required, based on the needs of the network in relation to any additional expertise required to successfully guide the delivery the network’s strategy.

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Institution/Company</th>
<th>Expertise</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Greenwood</td>
<td>Manson Professor of Clinical Tropical Medicine</td>
<td>London School of Hygiene and Tropical Medicine (LSHTM), UK</td>
<td>Prevention of acute infectious diseases, vaccine development &amp; evaluation</td>
</tr>
<tr>
<td>Richard Adegbola</td>
<td>Consultant &amp; Research Professor</td>
<td>Nigerian Institute of Medical Research</td>
<td>Medical Microbiology, bacterial infection research in Sub-Saharan Africa</td>
</tr>
<tr>
<td>Kate O’Brien</td>
<td>WHO IVB Director, Consultant Paediatrician</td>
<td>World Health Organisation</td>
<td>Paediatric infectious disease physician, epidemiologist and vaccinologist</td>
</tr>
<tr>
<td>Samir Saha</td>
<td>Executive Director</td>
<td>Child Health Research Foundation, Bangladesh</td>
<td>Conjugate vaccines, Public Health, policy and economics, Microbiology, Clinical Trials, Public Engagement</td>
</tr>
<tr>
<td>Kathleen Neuzil</td>
<td>Director</td>
<td>Center for Vaccine Development &amp; Global Health, University of Maryland School of Medicine</td>
<td>Global public health, infectious diseases, vaccine access &amp; delivery, vaccine safety</td>
</tr>
</tbody>
</table>

The Advisory Board may invite any person to attend its meetings, subject to the approval of the Chair of the Board.

**Administrative support**

- Susan Pope, BactiVac Network Administrator
- Evelina Balandyte-Shergill, BactiVac Network Administrator **
- Alice Darbyshire, BactiVac Network Administrator
- Catherine Hardy, BactiVac Network Communications Officer

** Evelina Balandyte-Shergill currently on extended leave**

**Frequency of meetings:**

The Advisory Board will meet face to face annually, normally to coincide with the Annual Network Meeting.